---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: false
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Lecture 1: Penicllin and antibiotic allergies {background-image="images/nejm_allergy.png" background-opacity="0.2"}

<br> <br> <br> <br> <br>

**Russell E. Lewis** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

![](images/unipd.png){.absolute top="550" left="950" width="100" height="100"}

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)

## Objectives

-   Describe the different types of hypersensitivity reactions based on clinical presentation and immunological mechanisms 

-   Recognise a patient history that will differentiate between immediate and delayed-type hypersensitivity reactions 

-   Describe the risk of cross-reactions between various beta-lactam antibiotics 

-   Describe the principles and contraindications for desensitisation

-   Describe the clinical manifestations, diagnosis and management of common non-beta-lactam antibiotic allergies

## On target vs. off-target drug effects

![](images/classification.png){fig-align="center"}

::: aside
[@macy.etal_2023]
:::

## Variable cutaneous presentation of <br>allergic drug reactions

<br>

::::::: columns
::: {.column width="25%"}
![widespread macupapular](images/widespreadmacular.png)
:::

::: {.column width="25%"}
![macupapular aspect](images/macupapular%20aspect.png)
:::

::: {.column width="25%"}
![isolated follicular](images/isolated%20foilicular.png)
:::

::: {.column width="25%"}
![coalescing erythema](images/coelscing%20erythema.png)
:::
:::::::

::: aside
Images: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel
:::

## Urticaria and angioedema {.smaller}

<br>

::::: columns
::: {.column width="50%"}
![urticaria](images/urticaria.png)
:::

::: {.column width="50%"}
![angioedema](images/angioendema.png)
:::
:::::

::: aside
Images: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel
:::

## **Acute generalised exanthematous pustulosis (AGEP)**

<br> <br>

::::: columns
::: {.column width="50%"}
![](images/ten.png)
:::

::: {.column width="50%"}
![](images/agep.png)
:::
:::::

::: aside
[@zhang.liu_2015]
:::

## Fixed drug eruption

<br>

![](images/fixed.png)

::: aside
Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel
:::

## **Erythema multiforme, Toxic epidermal necrolysis (TEN)**

<br>

![](images/ten2.png)

::: aside
Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel
:::

## **DRESS: Drug rash with eosinophilia** <br> and systemic symptoms {.smaller}

::::: columns
::: {.column width="40%"}
-   **Latency:** 2-8 weeks

-   **Non-specific symptoms:**

    -   Fever (75%), lymphadenopathy (55-65%)

-   **Hematological abnormalities:**

    -   **Eosinophilia \> 700 micolL (85-95%)**

    -   **Leukocytosis (95%)**

    -   **Neutrophilia (78%)**

    -   **Monocytosis (69%)**

    -   **Atypical lymphocytosis (35-67%)**

-   **Visceral involvement:**

    -   **Liver (53-90%)-cholestatic and/or hepatocellular**

    -   **Pulmonary (30%)-shortness of breath, cough**

    -   **Cardiac involvement (2-20%)- hypotension, tachycardia, dyspnea, LV dysfunction, myocarditis**
:::

::: {.column width="60%"}
![](images/dress.png)
:::
:::::

::: aside
Image: UptoDate
:::

## DRESS: Pathophysiology <br> and systemic symptoms {.smaller}

<br> <br>

::::: columns
::: {.column width="40%"}
-   **Pathophysiology:**

    -   Type IV T-cell activation (CD4+/CD8+) producing TNF-α

    -   Reactivation of viruses from the Herpesviridae family (eg, HHV-6, HHV-7, Epstein-Barr virus \[EBV\], cytomegalovirus \[CMV\]) occurs in up to 75 percent of patients-cause or consequence? 

    -   Some patient human leukocyte antigens are associated with higher risk
:::

::: {.column width="60%"}
![](images/dress.png)
:::
:::::

::: aside
Image: UptoDate
:::

## Classic "high-risk" drugs for DRESS

<br>

-   Allopurinol

-   Aromatic antiepileptic agents (carbamazepine, phenytoin, lamotrigine, …)

-   Sulfonamides

-   Vancomycin

-   Minocycline

-   Nevirapine

-   Anti-tuberculosis drugs

-   Mexiletine

**β-lactams are lower risk**

## Stevens-Johnson Syndrome

<br> <br>

![](images/SJ.png)

::: aside
Image: Kathrin Hoffmeier Sherer, M.D., Univ. of Basel
:::

## Modified Gell and Coombs Classification

<br>

![](images/coombs.png){width="800"}

::: aside
[@hausmann.etal_2010]
:::

## Immunological mechanisms <br> {.smaller}

![](images/nejm2.png){fig-align="center" width="400"}

::: aside
[@castells.etal_2019]
:::

## <br> <br> <br> <br> Penicillin allergy {background-image="images/amoxicillin.png" background-opacity="0.2"}

## Penicillin allergy epidemiology

<br>

-   10-20% of patients will report a history of an allergy to PCN therapy 

-   However, only 0.5%-2% of all PCN administrations actually result in hypersensitivity reactions, most often rash 

    -   Of these 1% are IgE mediated 

-   The incidence IgE PCN allergies is decreasing, partially due to the reduced use of parenteral PCN, which degradation products in solution may be the primary culprit 

-   Statistics from the UK 1972-2007 oral amoxicillin:

    -   1 death after anaphylaxis with oral amoxicillin (35 years and 100 million treatment courses)

-   Most reports of penicillin allergy describe unknown or cutaneous reaction

<br>

## Public health implications {.smaller}

![](images/public.png){fig-align="center" width="800"}

::: aside
[@castells.etal_2019]
:::

## So if a patient reports they have a <br> penicillin allergy... {.smaller}

<br>

::::: columns
::: {.column width="50%"}
**5% need allergy evaluation**

-   Recent history if true IgE type reaction

-   Blistering rash

-   Hemolytic anemia

-   Nephritis

-   Hepatitis

-   Fever and joint pain

-   Severe cutaneous adverse reaction (SCAR)
:::

::: {.column width="50"}
**95% can tolerate penicillins**

-   Delayed, benign rash (Type IV reaction) that often does not recur with rechallenge
-   True IgE reactions wane over time, with 80% becoming tolerant after 10 years 
-   Many patients were never allergic, but had other symptoms they though represented a PCN allergy (concurrent viral infection, GI distress)
:::
:::::

## Top 4 patient penicillin allergy myths {background-image="images/amoxicillin.png" background-opacity="0.2"}

<br>

-   **Once you have an penicillin allergy, you have it for life**

    -   Allergy wanes over time, 80% of patients with type I (IgE-mediated reactions) will not have an allergy after a 10 year period

-   **Viral rashes mistaken for antibiotic therapy**

    -   E.g., child with a viral exanthematous rash treated with a course of penicillin

    -   Pediatric studies have reported \>90% of children who developed rashes on antibiotic therapy do not develop a rash when rechallenged with penicillin again

-   **Adverse effects mistaken by the patient as drug allergy**

    -   E.g. diarrhea, stomach cramps

-   **“I have a family history of penicillin allergy”**

    -   No genetic basis has been identified for penicillin allergies

## Penicillin allergy history

<br>

![](images/history.png){fig-align="center"}

::: aside
[@shenoy.etal_2019]
:::

<br>

## Timing and clinical presentation of reaction is key

<br>

![](images/contraindications.png){fig-align="center"}

::: aside
[@shenoy.etal_2019]
:::

## How to assess patient risk

<br>

![](images/risk.png){fig-align="center"}

::: aside
[@shenoy.etal_2019]
:::

## PENFAST score {.smaller}

![](images/penfast.png){fig-align="center" width="800"}

::: aside
The PEN-FAST clinical decision rule for patients reporting a penicillin allergy uses 3 clinical criteria of time from penicillin allergy episode, phenotype, and treatment required. A total score is calculated using PEN-FAST score in the upper panel,and interpretation for risk strategy is provided in the lower panel. ^a^Includes unknown. ^b^Forms of severe delayed reactions include potential Stevens-Johnsonsyndrome, toxic epidermalnecrolysis, drug reaction witheosinophilia and systemicsymptoms, and acute generalizedexanthematous pustulosis. Patients with a severe delayed rash withmucosal involvement should beconsidered to have a severecutaneous adverse reaction. Acute interstitial nephritis, drug inducedliver injury, serum sickness andisolated drug fever were excluded phenotypes from the derivation and validation cohorts.

[@trubiano.etal_2020]
:::

## PENFAST performance

<br>

![](images/penfast_perf.png){fig-align="center"}

::: .aside
[@trubiano.etal_2020]
:::

## Direct oral amoxicillin challenge

![](images/amox_challenge.png){fig-align="center"}

::: .aside
[@macy.etal_2023]
:::

## Two step oral amoxicillin challenge

<br>

![](images/2step.png){fig-align="center"}

::: .aside
[@macy.etal_2023]
:::

## Anaphylaxis medications

![](images/anaphylaxis.png){fig-align="center"}

::: .aside
[@macy.etal_2023]
:::

## Skin testing

![](images/skintest.png){fig-align="center"}

::: .aside
[@macy.etal_2023]
:::

## Allergic determinates {.smaller}

:::::: columns
::: {.column width="50%"}
![](images/penicillins.png){width="200"}
:::

::: {.column width="50%"}
![](images/minor.png){width="200"}
:::

::: .aside
[@castells.etal_2019]
:::
::::::

## References

<br>
